Our data also suggest that in contrast to the inhibition of survivin phosphorylation using volasertib and barasertib, inhibition of survivin at the transcriptional level using YM155 is not sufficient to suppress tumor growth in AAs with TNBC. Here, BIRC5 is linked to neoplasm.